{"entity":{"id":"cyclin-d1-t11-14","kind":"term","name":"t(11;14), cyclin D1 and SOX11","aka":["t(11;14)(q13;q32)","CCND1 translocation","CCND1::IGH","IGH::CCND1","cyclin D1","cyclin D1 immunohistochemistry","cyclin D1-positive","cyclin D1-negative mantle cell lymphoma","SOX11","SOX11-negative","leukaemic non-nodal mantle cell lymphoma","t(11;14) myeloma","CCND1-translocated myeloma"],"tldr":"The t(11;14) translocation parks the cyclin D1 gene next to the antibody gene's accelerator, flooding the cell with a protein that pushes it through division; a brown nuclear stain for cyclin D1 (plus SOX11) is how mantle cell lymphoma is confirmed, and in myeloma the same translocation marks the patients who respond to venetoclax.","summary":"What is measured: the IGH::CCND1 translocation and the proteins that go with it. How: cyclin D1 immunohistochemistry (nuclear staining in over 95 percent of mantle cell lymphomas; the rare negatives carry CCND2 or CCND3 rearrangements and are caught by SOX11 positivity), FISH for CCND1::IGH on tissue, blood or marrow, karyotype, and SOX11 immunohistochemistry, which is positive in classic nodal mantle cell lymphoma and negative in the indolent leukaemic non-nodal form (IGHV-mutated, often CD5-negative). In myeloma, FISH panels find t(11;14) in 15 to 20 percent, a standard-risk lesion whose cells depend on BCL2, and more often in AL amyloidosis and plasma cell leukaemia. What a result changes: it separates mantle cell lymphoma from CLL and small lymphocytic lymphoma (cyclin D1-negative, LEF1-positive) and follicular lymphoma; SOX11-negative leukaemic non-nodal disease can often be observed; in myeloma, t(11;14) selects patients for venetoclax-based regimens (a BELLINI subgroup, CANOVA, and NCCN listing off label) and predicts BCL2-inhibitor response in AL amyloidosis. Where it matters: mantle cell lymphoma, plasma cell leukaemia and relapsed myeloma.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Cyclin_D1","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Cyclin_D1"}],"tags":[],"related":["mipi","bcl2","venetoclax","fish","ihc","cytogenetics","cdk4-6","high-risk-myeloma","ibrutinib"],"cancers":["mantle-cell-lymphoma","plasma-cell-leukaemia","myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Biomarkers"},"route":"/terms/cyclin-d1-t11-14/","neighbours":{"term":[{"id":"cytogenetics","kind":"term","name":"Cytogenetics and karyotype","route":"/terms/cytogenetics/"},{"id":"fish","kind":"term","name":"FISH / ISH (in situ hybridisation)","route":"/terms/fish/"},{"id":"high-risk-myeloma","kind":"term","name":"High-risk cytogenetics (myeloma)","route":"/terms/high-risk-myeloma/"},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/"},{"id":"mipi","kind":"term","name":"MIPI (Mantle Cell Lymphoma International Prognostic Index)","route":"/terms/mipi/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"}],"drug":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}]}}